FY2029 EPS Estimate for Kura Oncology Reduced by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Brookline Capital Markets reduced their FY2029 earnings per share (EPS) estimates for Kura Oncology in a note issued to investors on Wednesday, August 12th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn $5.70 per share for the year, down from their previous estimate of $6.01. The consensus estimate for Kura Oncology’s current full-year earnings is ($3.45) per share.

A number of other analysts have also commented on KURA. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, June 4th. CLSA set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Oppenheimer set a $24.00 target price on shares of Kura Oncology in a research report on Thursday, May 28th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $25.62.

Kura Oncology Price Performance

Shares of KURA opened at $10.09 on Friday. The business’s fifty day moving average is $10.17 and its 200 day moving average is $9.32. Kura Oncology has a 12-month low of $6.35 and a 12-month high of $12.49. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. The stock has a market cap of $895.69 million, a P/E ratio of -2.99 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 169.73% and a negative net margin of 384.30%.The firm had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million.

Insider Activity

In other news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares of the company’s stock, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares during the period. Strs Ohio purchased a new position in shares of Kura Oncology in the 1st quarter worth about $143,000. Legal & General Group Plc boosted its holdings in shares of Kura Oncology by 35.1% in the 2nd quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock worth $421,000 after buying an additional 18,930 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Kura Oncology by 13.0% in the 2nd quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock worth $686,000 after buying an additional 13,690 shares during the last quarter. Finally, American Century Companies Inc. grew its position in Kura Oncology by 244.5% during the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after buying an additional 165,189 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.